Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibitor Therapy SAN DIEGO, Dec. 2, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ:…

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks